


OptiNose founded in Oslo, Norway




Seed investment received, basic prototype developed



First clinical study conducted focusing on proving the hypothesis that bi-directional delivery is achieved and that lung deposition is avoided

[illegible]

Clinical trial conducted with influenza vaccine comparing four different administration devices – OptiNose device, conventional nasal spray, nasal drops and mouth spray




Clinical trial conducted with diphtheria vaccine comparing OptiNose device and conventional spray pump



December 2002

OptiNose receives first investment from Entrepreneurs Fund




November 2003

Clinical trial conducted with midazolam comparing OptiNose device with traditional nasal spray and IV



April 2004

United Kingdom office established



September 2004

Data on bi-directional nasal delivery prevent lung deposition published in Journal of Aerosol Medicine



December 2005

OptiNose receives a \$15 million investment from New York-based venture capital firm WFD Ventures




March 2006

Data on significantly improved dose deposition of the OptiNose device compared with conventional nasal spray published in Laryngoscope




March 2006

Clinical trial results of influenza vaccine and OptiNose device published in Scandinavian Journal of Immunology



May 2006

Phase I clinical trials for nasal polyps with fluticasone and OptiNose device conducted




July 2006

Phase I clinical trials for migraine headache with sumatriptan and OptiNose device conducted




October 2006

Clinical trial results of intranasal midazolam with OptiNose device published in Journal of Pharmacy and Pharmacology




April 2007

Phase II clinical trials for migraine headache with sumatriptan and OptiNose device conducted




May 2007

Phase II clinical trials for nasal polyps with fluticasone and OptiNose device conducted



September 2007

Phase II clinical trials for refractory chronic rhinosinusitis with fluticasone and OptiNose device conducted



March 2008

Phase I clinical trials with human insulin and OptiNose device conducted



June 2009

Phase I clinical trials for migraine headache with sumatriptan and OptiNose device published in Journal of Pharmacy and Pharmacology



September 2009

Method paper highlighting gammascintigraphy deposition in the human nose published in Nuclear Communication Medicine



December 2009

Phase II clinical trial results for nasal polyps with fluticasone and OptiNose device published in Rhinology



March 2010

Phase II clinical trial results for migraine headache with sumatriptan and OptiNose device published in Cephalgia



June 2010

OptiNose receives a \$48.5 million investment from New York-based private equity firm Avista Capital Partners



June 2010

OptiNose reincorporates its business in the United States and moved its headquarters from Oslo, Norway to Yardley, PA



June 2010

Peter Miller named President and Chief Executive Officer of OptiNose



August 2010

Phase II sub-group analysis in nasal polyps with fluticasone and OptiNose device published in American Journal of Rhinology and Allergy



September 2010

Phase II clinical trials results for refractory chronic rhinosinusitis with fluticasone and OptiNose device published in Rhinology